Xavier Valencia
Head of IBD Franchise Enveda Biosciences
Xavier brings an exceptional track record across multiple therapeutic areas and modalities. Most recently at Ventus Therapeutics, he led the development of a brain-penetrant NLRP3 inhibitor and a first-in-class cGAS inhibitor. His career spans leadership roles in gene & cell therapy (Tr1X), small molecules (Strongbridge Biopharma), and biologics (Boston Pharmaceuticals)—driving programs all the way from IND submission through to BLA/NDA filings
Seminars
Thursday 2nd April 2026
Roundtable Discussion: Advancing Patient Outcomes by Addressing Heterogeneity in Crohn’s Disease & Ulcerative Colitis
9:00 am
- Clinical complexity of Crohn’s Disease including fibrostenosis, fistula formation, and inflammation independent complications
- Limitations of current therapies that control inflammation but fail to resolve fibrosis or tissue damage
- Exploring unmet needs and future therapeutics from a clinicians perspective
